[Erythema multiforme following COVID-19 vaccination (BNT162b2)].

4区医学 Q3 Medicine

Hautarzt Pub Date : 2022-01-01 Epub Date: 2021-10-21 DOI:10.1007/s00105-021-04911-4

K Wunderlich, T Dirschka

引用次数: 9

Abstract

We report a case of a patient with erythema multiforme major following COVID-19 (coronavirus disease 2019) vaccination. Lesions on skin and mucous membranes developed 48 h after the second dose of the mRNA-vaccine BNT162b2 (Tozinameran, Comirnaty®). Under the application of external glucocorticoids complete resolution was achieved within 3 weeks.

Abstract Image

查看原文本刊更多论文

[COVID-19疫苗接种后多形性红斑(BNT162b2)]。

我们报告一例在COVID-19(冠状病毒病2019)疫苗接种后出现多形性红斑的患者。第二剂mrna疫苗BNT162b2 (Tozinameran, Comirnaty®)后48 h出现皮肤和粘膜病变。在外用糖皮质激素治疗下，3周内完全消退。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hautarzt 医学-皮肤病学

CiteScore

1.40

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： Der Hautarzt is an internationally recognized journal informing all dermatologists working in practical or clinical environments about important developments in the field of dermatology including allergology, venereology and related areas. Comprehensive reviews on a specific topical issue focus on providing evidenced based information on diagnostics and therapy. Freely submitted original papers allow the presentation of important clinical studies and serve the scientific exchange. Case reports feature interesting cases and aim at optimizing diagnostic and therapeutic strategies. Review articles under the rubric "Continuing Medical Education" present verified results of scientific research and their integration into daily practice.